DEVELOPING EUROPE & CIS

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis Portfolio, followed by High Potency & Cytotoxic Brands. The newly acquired Anaesthetics portfolio currently contributes 12% to regional revenue and is expected to become more significant over time.

Key Countries

Czech Republic
Poland
Romania
Russia
Slovakia

Contribution to Group revenue

Revenue contribution - by therapeutic category

Injectable anticoagulants across Developing Europe & CIS grew 6,1% by volume. Volumes in Russia grew 15,6% over the same period.

Source: June 2017 IMS

STATISTICS

Number of products launched:

Nil

(2016: nil)

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:

0 – 2 years

USDnil

3 – 5 years

USD1 million

Number of product recalls:

Nil

(2016: nil)

Average staff turnover:

13,7%

(2016: 14,2%)

Number of work-related fatalities:

Nil

(2016: nil)

Number of permanent employees:

Revenue – R’billion	2017	2016 (CER)*	% change
Total	2,6	2,3	16
Anaesthetics	0,3	–	>100
Thrombosis	1,7	1,8	(2)
High Potency & Cytotoxics	0,5	0,4	20
Other Commercial Pharmaceutical Brands	0,1	0,1	13

* Constant exchange rate: FY16 restated at FY17 average exchange rates.
Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.